Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | MARK3 | P27448 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420129 | 1.00 | JAK2 (0.52) | JAK2MAPK14KDM4DNUDT1LRRK2 | |
| SCHEMBL31240448 | 0.96 | JAK2 (0.51) | JAK2MAPK14KDM4DNUDT1LRRK2 | |
| SCHEMBL26686112 | 0.96 | JAK2 (0.51) | JAK2MAPK14KDM4DNUDT1LRRK2 | |
| SCHEMBL31240693 | 0.95 | JAK2 (0.50) | JAK2MAPK14KDM4DNUDT1LRRK2 | |
| SCHEMBL26685988 | 0.95 | JAK2 (0.50) | JAK2MAPK14KDM4DNUDT1LRRK2 | |
| SCHEMBL31240555 | 0.93 | JAK2 (0.55) | JAK2MAPK14LRRK2MAP4K4PDPK1 | |
| SCHEMBL26685748 | 0.93 | JAK2 (0.55) | JAK2MAPK14LRRK2MAP4K4PDPK1 | |
| SCHEMBL30633170 | 0.87 | JAK2 (0.51) | JAK2LRRK2MAP4K4PDPK1CDK1 | |
| SCHEMBL26886607 | 0.87 | JAK2 (0.51) | JAK2LRRK2MAP4K4PDPK1CDK1 | |
| SCHEMBL26686269 | 0.86 | JAK2 (0.50) | JAK2LRRK2MAP4K4PDPK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | JAK2 207/4885MAPK14 653/4885KDM4D 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.